Pharmacyclics, Inc.

Novartis Ag

University of Pennsylvania

The Ohio State University

Amy Jo Johnson

John C Byrd

Natarajan Muthusamy

Jason A Dubovsky

David Miklos

Carl H June

Tarak D Mody

Joseph J Buggy

Jennifer Brogdon

Saar Gill

David Jonathan Glass

Marcela V Maus

Joan Mannick

David L Porter

Leon Murphy

Marco Ruella

Anna Vulpetti

Mariusz Wasik

Daniela Angst

Saad Kenderian

William Raj Sellers

Betty Chang

David M Lucas

Michael R Grever

Joseph Fraietta

Emilia Mahoney

François Gessier

Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.

Methods of treating and preventing graft versus host disease

The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.

Treatment of cancer using anti-CD19 Chimeric Antigen Receptor

Described herein are methods and compositions comprising a covalent TEC family kinase inhibitor for use in adjuvant therapy, including adjuvant cancer therapy, vaccination and treatment of immune disorders and pathogenic infections.

TEC family kinase inhibitor adjuvant therapy

A method of (a) treating a lymphoproliferative disease in a subject in need thereof; (b) slowing the progression of lymphoproliferative disease in a subject who has been diagnosed with a lymphoproliferative disease; or (c) preventing or delaying development of a lymphoproliferative disease in a subject who is at risk of developing a lymphoproliferative disease. The method generally comprises administering to the individual an effective amount of a combination therapy comprising: i) at least one autophagy modulating agent, or a derivative, pharmaceutically acceptable salt thereof, or prodrug thereof; and ii) at least one CDK inhibitor agent, or a derivative, pharmaceutically acceptable salt thereof, or prodrug thereof, wherein the i) agent and the ii) agents are administered in amounts sufficient to enhance the cytotoxicity of the combination relative to the CDK inhibitor agent treatment alone.

Compositions and methods for increasing drug efficacy in cancer

Growing community of inventors

Columbus, OH, United States of America

Amy Jo Johnson